{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T20:45:42Z","timestamp":1761597942975,"version":"3.37.3"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Council of Technological and Scientific Development"},{"DOI":"10.13039\/501100002322","name":"Coordination for the Improvement of Higher Education Personnel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To determine whether the drug saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor which is utilized for the treatment of Diabetes Mellitus, has neuroprotective effects in the animal model of Parkinson's disease (PD) induced by 6-hydroxydopamine (6-OHDA) in rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Male Wistar rats (weighing 280\u2013300 g) received a bilateral infusion of 6-OHDA in the substantia nigra. Twenty-four hours later, they were treated with saxagliptin (1 mg\/kg, p.o) once daily, for 21 days. The motor function was evaluated using the open field and rotarod (RT) tests. In addition, cognition was assessed with the novel object recognition test (ORT). After the evaluation of the behavioural tests, the animals were transcardially perfused to perform immunohistochemistry staining for tyrosine hydroxylase (TH) in the substantia nigra pars compacta (SNpc).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>Saxagliptin impaired the memory of animals in the sham group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Saxagliptin treatment did not exhibit neuroprotection and it did not improve the cognitive and motor deficits in the 6-OHDA model of PD. Interestingly, when saxagliptin was administered to the sham animals, a cognitive decline was observed. Therefore, this drug should be investigated as a possible treatment for PTSD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/jphp.12936","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T07:41:56Z","timestamp":1526456516000},"page":"1059-1068","source":"Crossref","is-referenced-by-count":11,"title":["Ineffectiveness of saxagliptin as a neuroprotective drug in 6-OHDA-lesioned rats"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6020-4211","authenticated-orcid":false,"given":"Joelle de Melo","family":"Turnes","sequence":"first","affiliation":[{"name":"Pharmacology Department, Biological Sciences Sector, Federal University of Paran\u00e1 , Curitiba,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taysa Bervian","family":"Bassani","sequence":"additional","affiliation":[{"name":"Pharmacology Department, Biological Sciences Sector, Federal University of Paran\u00e1 , Curitiba,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo C","family":"Souza","sequence":"additional","affiliation":[{"name":"Pharmacology Department, Biological Sciences Sector, Federal University of Paran\u00e1 , Curitiba,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A B F","family":"Vital","sequence":"additional","affiliation":[{"name":"Pharmacology Department, Biological Sciences Sector, Federal University of Paran\u00e1 , Curitiba,","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,8,1]]},"reference":[{"key":"2024103012310445100_jphp12936-cit-0001","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrneurol.2012.242","article-title":"100 years of Lewy pathology","volume":"9","author":"Goedert","year":"2012","journal-title":"Nat Rev Neurol"},{"key":"2024103012310445100_jphp12936-cit-0002","first-page":"1","article-title":"Dissecting the role of Engrailed in adult dopaminergic neurons \u2013 insights into Parkinson disease pathogenesis","volume":"24 Pt A","author":"Rekaik","year":"2015","journal-title":"FEBS Lett"},{"key":"2024103012310445100_jphp12936-cit-0003","first-page":"1","article-title":"Improving the treatment of Parkinson's disease: a novel approach by modulating 5-HT1A receptors","volume":"4","author":"Shimizu","year":"2013","journal-title":"Aging Dis"},{"key":"2024103012310445100_jphp12936-cit-0004","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/jnc.13750","article-title":"Current and experimental treatments of Parkinson disease: a guide for neuroscientists","volume":"139","author":"Oertel","year":"2016","journal-title":"J Neurochem"},{"key":"2024103012310445100_jphp12936-cit-0005","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2174\/18715273113126660155","article-title":"Does Parkinson's disease and type-2 diabetes mellitus present common pathophysiological mechanisms and treatments?","volume":"13","author":"Lima","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"2024103012310445100_jphp12936-cit-0006","doi-asserted-by":"crossref","first-page":"910","DOI":"10.2337\/dc10-1922","article-title":"Diabetes and risk of Parkinson's disease","volume":"34","author":"Xu","year":"2011","journal-title":"Diabetes Care"},{"key":"2024103012310445100_jphp12936-cit-0007","doi-asserted-by":"crossref","first-page":"842","DOI":"10.2337\/dc06-2011","article-title":"Type 2 diabetes and the risk of Parkinson\u2019 s disease","volume":"30","author":"Hu","year":"2007","journal-title":"Diabetes Care"},{"key":"2024103012310445100_jphp12936-cit-0008","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1210\/jcem-33-5-829","article-title":"Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa","volume":"33","author":"Boyd","year":"1971","journal-title":"J Clin Endocrinol Metab"},{"key":"2024103012310445100_jphp12936-cit-0009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/0021-9681(74)90031-9","article-title":"Glucose intolerance in Parkinson's disease","volume":"27","author":"Lipman","year":"1974","journal-title":"J Chronic Dis"},{"key":"2024103012310445100_jphp12936-cit-0010","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0301-0082(91)90015-S","article-title":"Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects","volume":"36","author":"Unger","year":"1991","journal-title":"Prog Neurobiol"},{"key":"2024103012310445100_jphp12936-cit-0011","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/0306-4522(91)90049-T","article-title":"Immunohistochemical localization of insulin receptors and phosphotyrosine in the brainstem of the adult rat","volume":"42","author":"Unger","year":"1991","journal-title":"Neuroscience"},{"key":"2024103012310445100_jphp12936-cit-0012","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.molmed.2013.01.002","article-title":"Shared dysregulated pathways lead to Parkinson's disease and diabetes","volume":"19","author":"Santiago","year":"2013","journal-title":"Trends Mol Med"},{"key":"2024103012310445100_jphp12936-cit-0013","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuropharm.2014.10.007","article-title":"Saxagliptin: a novel antiparkinsonian approach","volume":"89","author":"Nassar","year":"2015","journal-title":"Neuropharmacology"},{"key":"2024103012310445100_jphp12936-cit-0014","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.drudis.2016.01.013","article-title":"The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action","volume":"21","author":"Athauda","year":"2016","journal-title":"Drug Discov Today"},{"key":"2024103012310445100_jphp12936-cit-0015","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/14740338.2013.741584","article-title":"Saxagliptin overview: special focus on safety and adverse effects","volume":"12","author":"Ali","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"2024103012310445100_jphp12936-cit-0016","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.neuropharm.2013.04.008","article-title":"Saxagliptin: a dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease","volume":"72","author":"Kosaraju","year":"2013","journal-title":"Neuropharmacology"},{"key":"2024103012310445100_jphp12936-cit-0017","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/dom.12432","article-title":"Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline","volume":"17","author":"Gault","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"2024103012310445100_jphp12936-cit-0018","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.physbeh.2015.09.007","article-title":"Neuroprotective effect of selective DPP-4 inhibitor in experimental vascular dementia","volume":"152","author":"Jain","year":"2015","journal-title":"Physiol Behav"},{"key":"2024103012310445100_jphp12936-cit-0019","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jnc.13087","article-title":"Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFKB and Nrf2-antioxidant signaling pathways","volume":"133","author":"Abdelsalam","year":"2015","journal-title":"J Neurochem"},{"key":"2024103012310445100_jphp12936-cit-0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.bbr.2013.10.035","article-title":"Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin","volume":"259","author":"Santiago","year":"2014","journal-title":"Behav Brain Res"},{"key":"2024103012310445100_jphp12936-cit-0021","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2005","edition":"5th"},{"key":"2024103012310445100_jphp12936-cit-0022","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-60761-303-9","volume-title":"The Open Field Test. Mood and Anxiety Related Phenotypes in Mice","author":"Gould","year":"2009"},{"volume-title":"A Study of the Rat's Behavior in a Field: A Contribution to Method in Comparative Psychology","year":"1932","author":"Hall","key":"2024103012310445100_jphp12936-cit-0023"},{"key":"2024103012310445100_jphp12936-cit-0024","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.pnpbp.2010.06.004","article-title":"Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine","volume":"34","author":"Santiago","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2024103012310445100_jphp12936-cit-0025","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2011.10.057","article-title":"Neurotoxin-based models of Parkinson's disease","volume":"211","author":"Bov\u00e9","year":"2012","journal-title":"Neuroscience"},{"key":"2024103012310445100_jphp12936-cit-0026","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2014.09.068","article-title":"Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats","volume":"1593","author":"Bassani","year":"2014","journal-title":"Brain Res"},{"key":"2024103012310445100_jphp12936-cit-0027","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jneumeth.2006.06.001","article-title":"Comparison of incremental and accelerating protocols of the rotarod test for the assessment of motor deficits in the 6-OHDA model","volume":"158","author":"Monville","year":"2006","journal-title":"J Neurosci Methods"},{"key":"2024103012310445100_jphp12936-cit-0028","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/S0006-8993(96)01162-6","article-title":"Drug-free evaluation of rat models of parkinsonism and nigral grafts using a new automated rotarod test","volume":"749","author":"Rozas","year":"1997","journal-title":"Brain Res"},{"key":"2024103012310445100_jphp12936-cit-0029","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.expneurol.2013.01.003","article-title":"The interaction between the dopaminergic forebrain projections and the medial prefrontal cortex is critical for memory of objects: implications for Parkinson's disease","volume":"247","author":"Chao","year":"2013","journal-title":"Exp Neurol"},{"key":"2024103012310445100_jphp12936-cit-0030","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0166-4328(05)80315-8","article-title":"A new one-trial test for neurobiological studies of memory in rats. III. Spatial vs. non-spatial working memory","volume":"51","author":"Ennaceur","year":"1992","journal-title":"Behav Brain Res"},{"key":"2024103012310445100_jphp12936-cit-0031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.bbr.2014.08.002","article-title":"Assessing rodent hippocampal involvement in the novel object recognition task. A review","volume":"285","author":"Cohen","year":"2015","journal-title":"Behav Brain Res"},{"key":"2024103012310445100_jphp12936-cit-0032","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bbr.2016.03.019","article-title":"Neurosteroid allopregnanolone attenuates cognitive dysfunctions in 6-OHDA-induced rat model of Parkinson's disease","volume":"305","author":"Nezhadi","year":"2016","journal-title":"Behav Brain Res"},{"key":"2024103012310445100_jphp12936-cit-0033","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.nlm.2011.06.015","article-title":"Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats","volume":"96","author":"de Bruin","year":"2011","journal-title":"Neurobiol Learn Mem"},{"key":"2024103012310445100_jphp12936-cit-0034","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2006.12.032","article-title":"The COX-2 inhibitor parecoxib produces neuroprotective effects in MPTP-lesioned rats","volume":"560","author":"Reksidler","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"2024103012310445100_jphp12936-cit-0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.pnpbp.2014.02.009","article-title":"PPAR-\u03b1 agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson's disease","volume":"53","author":"Barbiero","year":"2014","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2024103012310445100_jphp12936-cit-0036","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0306-4522(97)00189-9","article-title":"Immunohistochemical studies on phosphorylation of tyrosine hydroxylase in central catecholamine neurons using site- and phosphorylation state- specific antibodies","volume":"82","author":"Xu","year":"1997","journal-title":"Neuroscience"},{"key":"2024103012310445100_jphp12936-cit-0037","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0306-4522(92)90502-S","article-title":"Sub-populations of pars compacta neurons in the substantia nigra: the significance of qualitatively and quantitatively distinct conductances","volume":"48","author":"Nedergaard","year":"1992","journal-title":"Neuroscience"},{"key":"2024103012310445100_jphp12936-cit-0038","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1517\/14656566.2015.978289","article-title":"A review of gliptins for 2014","volume":"16","author":"Scheen","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"2024103012310445100_jphp12936-cit-0039","doi-asserted-by":"crossref","DOI":"10.1002\/0471142301.ns0812s15","article-title":"Motor coordination and balance in rodents","author":"Carter","year":"2001","journal-title":"Curr Protoc Neurosci"},{"key":"2024103012310445100_jphp12936-cit-0040","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12933-015-0218-z","article-title":"DPP-4 inhibition with linagliptin ameliorates cognitive impairment and brain atrophy induced by transient cerebral ischemia in type 2 diabetic mice","volume":"14","author":"Ma","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2024103012310445100_jphp12936-cit-0041","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.brainres.2016.05.038","article-title":"Characterization of liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in rat partial and full nigral 6-hydroxydopamine lesion models of Parkinson's disease","volume":"1643","author":"Hansen","year":"2016","journal-title":"Brain Res"},{"key":"2024103012310445100_jphp12936-cit-0042","first-page":"211","article-title":"Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis","volume":"3","author":"Hansen","year":"2008","journal-title":"Interv Aging"},{"key":"2024103012310445100_jphp12936-cit-0043","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1476-5381.2011.01426.x","article-title":"Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease","volume":"164","author":"Duty","year":"2011","journal-title":"Br J Pharmacol"},{"volume-title":"Controversies on New Animal Models of Parkisnon's Disease Pro and Con: The Rotenone Model of Parkinson's Disease (PD)","year":"2006","author":"Schmidt","key":"2024103012310445100_jphp12936-cit-0044"},{"key":"2024103012310445100_jphp12936-cit-0045","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.npep.2016.02.007","article-title":"Identifying neuropeptide Y (NPY) as the main stress-related substrate of dipeptidyl peptidase 4 (DPP4) in blood circulation","volume":"57","author":"Wagner","year":"2016","journal-title":"Neuropeptides"},{"key":"2024103012310445100_jphp12936-cit-0046","doi-asserted-by":"crossref","first-page":"368703","DOI":"10.1155\/2014\/368703","article-title":"The nonglycemic actions of dipeptidyl peptidase-4 inhibitors","volume":"2014","author":"Kim","year":"2014","journal-title":"Biomed Res Int"},{"key":"2024103012310445100_jphp12936-cit-0047","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CMED.S5114","article-title":"Saxagliptin: a selective DPP-4 inhibitor for the treatment of type 2 diabetes mellitus","volume":"4","author":"Shubrook","year":"2011","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"key":"2024103012310445100_jphp12936-cit-0048","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.vascn.2014.11.002","article-title":"Establishment of a dipeptidyl peptidases (DPP) 8\/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors","volume":"71","author":"Huan","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"key":"2024103012310445100_jphp12936-cit-0049","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5","article-title":"Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system","volume":"403","author":"Merchenthaler","year":"1999","journal-title":"J Comp Neurol"},{"key":"2024103012310445100_jphp12936-cit-0050","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1002\/cne.23282","article-title":"Glucagon-like peptide-1 in the rat brain: distribution of expression and functional implication","volume":"521","author":"Gu","year":"2013","journal-title":"J Comp Neurol"},{"key":"2024103012310445100_jphp12936-cit-0051","article-title":"Cotinine: a therapy for memory extinction in post-traumatic stress disorder","author":"Mendoza","year":"2018","journal-title":"Mol Neurobiol"},{"key":"2024103012310445100_jphp12936-cit-0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2015.57","article-title":"Post-traumatic stress disorder","volume":"1","author":"Yehuda","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2024103012310445100_jphp12936-cit-0053","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.neuroscience.2017.07.018","article-title":"Effects of cannabinoid drugs on aversive or rewarding drug-associated memory extinction and reconsolidation","volume":"370","author":"Stern","year":"2018","journal-title":"Neuroscience"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.12936","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/8\/1059\/60223229\/jphp12936.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/70\/8\/1059\/60223229\/jphp12936.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T17:37:23Z","timestamp":1730309843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/70\/8\/1059\/6121809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":53,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8,1]]},"published-print":{"date-parts":[[2018,8,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.12936","relation":{},"ISSN":["2042-7158","0022-3573"],"issn-type":[{"type":"electronic","value":"2042-7158"},{"type":"print","value":"0022-3573"}],"subject":[],"published-other":{"date-parts":[[2018,8]]},"published":{"date-parts":[[2018,8,1]]}}}